|
Market Closed -
Sao Paulo
15:43:07 2026-10-28 EDT
|
5-day change | 1st Jan Change | ||
| 9.230 BRL | +4.41% |
|
+25.92% | -55.84% |
| 10-19 | Ultragenyx Pharmaceutical Enters Settlement With Navinta Over Dojolvi | MT |
| 10-14 | Ultragenyx Pharmaceutical to Sell Priority Review Voucher for $203 Million | DJ |
| Market Cap | 1.69B 9.08B 1.52B 1.4B 1.27B 2.37B 161B 2.4B 16.77B 6.68B 84.25B 6.34B 6.21B 267B | P/E 2026 * |
-4.62x | P/E 2027 * | -30.1x |
|---|---|---|---|---|---|
| Enterprise Value | 1.26B 6.79B 1.13B 1.05B 949M 1.77B 120B 1.8B 12.53B 4.99B 62.98B 4.74B 4.64B 200B | EV / Sales 2026 * |
1.66x | EV / Sales 2027 * | 1.16x |
| Free-Float |
96.28% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Ultragenyx Pharmaceutical Inc.
| 1 day | +4.41% | ||
| 1 week | +25.92% | ||
| Current month | +23.56% | ||
| 1 month | +24.73% | ||
| 3 months | -42.17% | ||
| 6 months | -22.63% | ||
| Current year | -55.84% |
| 1 week | 8.58 |  | 9.26 |
| 1 month | 7.07 | | 9.26 |
| Current year | 6.68 | | 18.64 |
| 1 year | 6.68 | | 20.9 |
| 3 years | 6.68 | | 33.03 |
| 5 years | 6.68 | | 39.36 |
| 10 years | 6.68 | | 39.36 |
| Manager | Title | Age | Since |
|---|---|---|---|
Emil Kakkis
CEO | Chief Executive Officer | 65 | 2010-04-21 |
Howard Horn
DFI | Director of Finance/CFO | 49 | 2023-10-15 |
Eric Crombez
CTO | Chief Tech/Sci/R&D Officer | 53 | 2023-04-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Emil Kakkis
BRD | Director/Board Member | 65 | 2010-04-21 |
Matthew Fust
BRD | Director/Board Member | 62 | 2013-12-31 |
Michael Narachi
BRD | Director/Board Member | 66 | 2015-02-19 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +4.41% | +25.92% | - | - | 1.65B | |
| +0.50% | +1.38% | +57.09% | +129.96% | 1,143B | |
| +0.86% | +5.14% | +45.00% | +86.15% | 647B | |
| -0.14% | +0.42% | +25.69% | +105.85% | 506B | |
| -0.05% | +1.73% | +52.74% | +67.74% | 384B | |
| -0.63% | -5.97% | +61.93% | +37.06% | 350B | |
| +0.34% | +1.84% | +30.70% | +54.27% | 293B | |
| -0.45% | +1.19% | +2.89% | +26.08% | 265B | |
| +0.87% | +3.08% | +54.69% | +72.74% | 242B | |
| +0.08% | +3.67% | +35.05% | +107.78% | 197B | |
| Average | +0.58% | +1.45% | +40.64% | +76.40% | 447.5B | |
| Weighted average by Cap. | +0.26% | +1.55% | +44.50% | +89.02% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 760M 4.08B 682M 631M 571M 1.07B 72.4B 1.08B 7.54B 3B 37.89B 2.85B 2.79B 120B | 997M 5.36B 895M 827M 749M 1.4B 94.96B 1.42B 9.89B 3.94B 49.69B 3.74B 3.66B 158B |
| Net income | -390M -2.1B -350M -324M -293M -548M -37.19B -555M -3.87B -1.54B -19.46B -1.47B -1.43B -61.78B | -72.28M -388M -64.85M -59.95M -54.3M -101M -6.88B -103M -717M -286M -3.6B -271M -266M -11.44B |
| Net Debt | -427M -2.29B -383M -354M -321M -599M -40.66B -606M -4.23B -1.69B -21.28B -1.6B -1.57B -67.55B | -531M -2.86B -477M -441M -399M -746M -50.62B -755M -5.27B -2.1B -26.49B -1.99B -1.95B -84.09B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-28 | R$9.230 | +4.41% | 1,531 |
| 26-10-27 | R$8.840 | +1.61% | 124 |
| 26-10-26 | R$8.700 | +21.17% | 420 |
| 26-10-22 | R$7.180 | -2.05% | 1 |
| 26-10-20 | R$7.330 | -2.01% | 3 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- RARE Stock
- R2AR34 Stock
Select your edition
All financial news and data tailored to specific country editions
